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for expensive intramural drugs in The Netherlands. The procedure
involves a 4-year period of conditional reimbursement. During this
period, additional evidence has to be gathered usually through a patient
registry. Given the costs and time involved in gathering the data, it is
important to carefully evaluate the registry. Objectives: This study
aimed to develop a model for the regular evaluation of patient registries
during an access with evidence development process and ﬁnd the
optimal length of the registry period. Methods: We used data from a
recent registry in The Netherlands on oxaliplatin as a treatment option
for stage III colon cancer. We added simulated follow-up data to the
empirical data available and applied value of information analysis to
balance the gains of extending the period and amount of data gathering
against the costs of registering patients. Results: We show that givenee front matter Copyright & 2015, International S
r Inc.
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ndence to: Leyla Mohseninejad, PO Box 30.001, Hathe assumptions on cohort size, follow-up time, and purpose of the
registry, the current (partly simulated) registry was not very efﬁcient.
Notably, the observation period could have been stopped to make a
deﬁnite reimbursement decision after a maximum of 2 years rather than
the ﬁxed 4-year period. Conclusions: Patient registries may be an
efﬁcient way to gather data on new medical treatments, but they need
to be carefully designed and evaluated, in particular regarding their
follow-up time. For each purpose, data gathering can be tailored to make
sure decisions are taken at the moment that sufﬁcient data are available.
Keywords: access with evidence development, decision theory, patient
registry, reimbursement, value of information.
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The uncertainty in costs and effectiveness of new medical tech-
nologies makes it risky for decisionmakers to decide on reimburse-
ment right after their market approval by authorities. However, it is
essential to keep pace with the rapid development in the ﬁeld of
medical innovations. In recent years, the concept of “access with
evidence development” (AED) has been introduced as a policy
option to balance the careful evaluation of new technologies with
improvements in patient care by rapid access to technologies.
In The Netherlands, conditional reimbursement has been
implemented as a way to ensure access while new evidence is
being gathered. The current regulation is still under develop-
ment, but previous regulation included a period of 4 years [1] in
which the drug was reimbursed under the condition that during
this period sufﬁcient information on its cost-effectiveness would
be obtained. After the collection of data in this period, the cost-
effectiveness of the drug is to be reassessed to make a deﬁnitereimbursement decision. Given the rather ad-hoc decision on the
4-year period (it actually was 3 years originally), the question
arises how long should the period of additional data gathering
last; that is, what is the best time for reevaluation? It seems
obvious that this will depend on the condition and the drug at
stake. That is, efﬁciency improvements must be possible over
and above the standard 4-year evaluation period. This is the
focus of the present study.
Although randomized controlled trials are considered the
criterion standard for gathering data on drug (cost-) effectiveness,
patient registries are more attractive in conditional reimburse-
ment settings. This is because additional clinical trials are
difﬁcult to organize in the same population in which a new
medication is already adopted and reimbursed, even condition-
ally. Ideally, a formal value of information (VOI) analysis, along
with full information on costs and expected outcomes of all
possible forms of research, would inform the choice of an optimal
research design [2]. The research decision space could also beociety for Pharmacoeconomics and Outcomes Research (ISPOR).
nzeplein 1, 9700 RB Groningen, The Netherlands.
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best research design [3]. Perhaps the most efﬁcient way of
gathering additional data would be using an optimal portfolio
of research combining different types of study designs including
trials, epidemiological studies, surveys, and patient registries [4].
Staying closer to actual practice, however, registries are used
without a VOI analysis being performed a priori.
Because of lack of randomization, registries have a serious
risk of biased outcomes. This limitation may be managed to some
extent by good design [5] and using analysis techniques such as
propensity scores [6]. Because the present study is an example to
illustrate how our methods for timing the reassessment and
data-gathering period may work, these techniques were left
aside.
Advantages of registries are that these reﬂect daily practice
more closely and can include a larger population than do
randomized studies because these do not require patients to
agree to randomization for their treatment. Therefore, registries
may be important sources of evidence [7].
The current research hence focuses on patient registries as
the source of additional data gathering. Setting up and maintain-
ing a registry is usually costly and time consuming, and so it is
important to evaluate its added value, both in advance and
during the registry period. If a registry aiming to support a
reimbursement decision does not produce, or is no longer
producing information helpful for that decision, it is not worth-
while to further delay the deﬁnite decision. In some cases, it
might even be better to stop the registry and to use other sources
of data (e.g., international trials) instead, unless other purposes
warrant its continuation.
Although the registry helps to gain new information and
hence to reduce the uncertainty in the decision, it imposes costs
consisting of set-up costs and costs of registering patients.
Moreover, during the conditional reimbursement period, no
deﬁnite decision is taken and patients may receive suboptimal
treatment as a result. In the Methods and Results sections, we
explain how these may be balanced to evaluate the registry and
ﬁnd the best length for the period of additional data gathering.
The discussion relates our ﬁndings to the actual data observation
and decision process and considers how the process could be
improved, changing the ﬁxed 4-year period in the current
regulations to a more ﬂexible period.Methods
Case Description
Our study concerns evaluating a registry used to support a
reimbursement decision for the speciﬁc case study of third-line
colon cancer treatment. We estimate the optimal duration of
getting data from the registry. This duration could be very short
or zero, actually indicating that the registry in its current form is
not expected to add useful information for the decision concern-
ing reimbursement. It might also be longer than actual follow-up,
indicating that the follow-up time could have been longer to
ensure a better decision.
Colon and rectal cancers are among the most common causes
of death from cancer, with 447,000 new cases and 215,000 deaths
in Europe in 2012 [8]. Since the 1990s, patients with stage III colon
cancer were treated by adjuvant chemotherapy with 5-
ﬂuorouracil and leucovorin (5FU/LV) [9]. From 2005 onwards,
National guidelines in The Netherlands have recommended the
use of 6 months of treatment with 5FU/LV combined with
oxaliplatin (FOLFOX) as the primary treatment option for patients
with stage III and possibly high-risk stage II colon cancer. As an
alternative, the use of capecitabine combined with oxaliplatin(CAPOX) was also supported by the Dutch Association for Medical
Oncology (Nederlandse Vereniging voor Medische Oncologie) [10].
Treatment costs with oxaliplatin are quite high; hence, the
majority (80%) of oxaliplatin costs were reimbursed to hospitals
in The Netherlands as of 2006 while a registry was initiated to
provide additional information. This registry was set up to collect
additional evidence during the conditional reimbursement
period. It has also provided information on guideline implemen-
tation in daily practice with respect to treatment choice, patient
characteristics, and dosage quantities [10]. The main question to
be answered in the reevaluation was whether or not oxaliplatin
should be allowed unconditional reimbursement. That is, the
relevant comparisons were treatments including oxaliplatin ver-
sus treatments without oxaliplatin.
General Approach
The evaluation of the registry was modeled using a wait-and-see
process. In such a process, the data are observed over time and
the model is updated using the observed data, until gathering
more information is not worthwhile anymore. We assume that
the data gathering can be stopped once the costs of the registry
exceed the gains. Using a health care perspective, we assumed
that the deﬁnite reimbursement decision would get informed by
the distribution of incremental net beneﬁts (INBs). The INB was
calculated as λ ðSo  ScÞ  ðCo  CcÞ, where λ represents the
willingness-to-pay threshold per disease-free life-day (DFLD)
gained, So shows the DFLDs when using oxaliplatin (FOLFOX or
CAPOX), Sc shows the DFLDs in the control population (5FU/LV or
capecitabine), and Co and Cc, respectively, are the total costs for
both types of treatment. A positive INB value indicates that
oxaliplatin is dominating the control treatment and is qualiﬁed
for reimbursement. Starting with an initial distribution for INB at
t0 (the starting point of the conditional reimbursement period),
the distribution of INB was updated periodically using the
registry data. In this way, the gain in information from the
registry for the reimbursement decision was directly evaluated.
Given disease prevalence and incidence, annual reevaluation was
assumed. Patients included in the registry were diagnosed in the
period 2005-2006; hence, the end of each year between 2006 and
2012 could have been a decision point (in 2012, the t ¼ 4 decision
was scheduled, and almost all patients experienced a relapse).
Having consecutive distributions of the INB, we calculated the
gains obtained from the additional information after each year.
Balancing these gains against the costs of the registry enabled us
to evaluate the registry and decide on the optimal time of making
a decision.
It must be noted that the current tool is intended to be used to
optimize the time of a reevaluation, not to calculate a posteriori
the value of a study. Hence, in actual practice, the method must
be applied to prospective data.
Patient Population
The registry data were gathered retrospectively during 2008-2009.
The database includes 391 patients with stage III colon cancer
receiving adjuvant therapy (see [10] for detailed inclusion crite-
ria), of which 281 patients had been treated with oxaliplatin
(FOLFOX in 136 patients and CAPOX in145 patients). The remain-
ing patients received capecitabine (93 patients) or 5FU/LV (17
patients). Follow-up time before a relapse or censoring was
reported and used to estimate disease-free survival (DFS). Drug
costs and follow-up costs were also registered [10].
Prediction of Missing Data Values
Some patients did not have a relapse and were censored at the
end of the data collection period. For the purpose of this study,
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have been gathered beyond 2008-2009. Therefore, from 2009
onwards, simulation was used to project the remainder of each
patient’s lifetime. The simulation was based on Weibull distri-
butions for DFLDs ﬁtted to the available patient data. Using
conditional survivals, the expected future life expectancies were
computed for all patients (see Appendix 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.008).
Medical costs were observed for the period 2005-2008 and used
to simulate treatment costs and follow-up costs for the remain-
ing years. We used constant costs per day for the treatment
phase and a gamma distribution on the proportion of total costs
in each time interval during the follow-up phase, based on
opinions of the involved experts (for more details, see Appendix
2 in Supplemental materials found at http://dx.doi.org/10.1016/j.
jval.2014.10.008). This resulted in a partly empirical, partly
simulated database covering the periods 2005-2009 and 2010-
2012, containing information on all patients diagnosed in 2005-
2006.
Survivals, Costs, and INBs
Because the purpose was to evaluate the registry at potential
points of making a deﬁnite decision, we looked at the data at the
end of each year as if there would be no more information
available after that date. This mimics how the procedure could be
used prospectively for a new decision, using a completely
empirical database.
For each year, we ﬁltered the (partly simulated) DFS to ﬁnd the
patients who had started treatment before the end of that year. If
the patient experienced no event before the end of the year, the
patient was censored for that year. The costs were simulated for
all patients during their treatment and follow-up time. When a
patient is censored, the costs up to the censor point were
considered (see Appendix 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.10.008).
This resulted in seven different data sets containing the data
observed up to the end of each year. These were analyzed to ﬁnd
their overall mean and standard errors of survivals and costs,
taking account of censoring.
Because of the severity of the condition, we assumed a rather
large λ of €60,000/disease-free life-year gained (€82/DFLD) in the
base case. We changed this in the sensitivity analysis. The
expected INB at the end of each year i was calculated as follows:
INBi¼ðλ=365Þ  ½EiðSoÞ  EiðScÞ  ½EiðCoÞ  EiðCcÞ ð1Þ
where Ei(X) shows the mean of parameter X at the end of the year
i. Assuming independency between costs and the DFS time, the
squared standard error of INBi then is
s:e2INBi ¼ðλ=365Þ
2  ½s:eiðSoÞ2þs:eiðScÞ2þ½s:eiðCoÞ2þs:eiðCcÞ2 ð2Þ
This can be estimated for each year, using the number of patients
in the registry at the end of each year (ni).
Prior Distribution of INB
The distribution for INB at t0 (the start of the conditional reimburse-
ment period) reﬂects the information available when the original
decision to set up the registry was made. This distribution is called
the prior distribution in a Bayesian analysis [11].
Using the Multicenter International Study of Oxaliplatin/Fluo-
rouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer
(MOSAIC) trial [12], we found a mean and standard error for DFS
days in each arm. Cost estimates used by decision makers at t0
were obtained from consultations with experts involved in the
registry. We assumed that the additional costs of oxaliplatin per
patient per treatment at t0 had a uniform distribution with
parameters (€0, €25,000). Follow-up costs were equal fortreatment with or without oxaliplatin as an initial estimate.
The expected INB and its standard error at t0 were then calculated
as follows:
INB0¼ðλ=365Þ  ½E0ðDSÞ½E0ðDCÞ ð3Þ
and
s:e2INB0 ¼ðλ=365Þ2  ðs:e0ðDSÞÞ2þðs:e0ðDCÞÞ2 ð4Þ
where DS and DC indicate the additional survival and additional
costs of oxaliplatin, respectively.
INB Updates
Having a prior distribution for INB and expressions for its
observation in each stage, we used a Bayesian approach to
update the INB values after each stage, calculating the posterior
by combining the prior with the information gathered during that
stage. The new prior was then this posterior.
For notational simplicity, it is convenient to reexpress the
standard errors as the precision:
τi 
1
ni  s:e2INBi
i¼0, 1, 2, …tm ð5Þ
where n0 is the number of patients in the initial trial (2246 in total
[12]), tm is the maximum time considered for the model, and ni
(I ¼ 1,…, tm) is the total number of patients in the registry in year
i. After observing INBi, the posterior of INB with respect to INBi
would be as follows [11]:
INBjINBiN
τ0
τ0þniτi
INB0þ niτi
τ0þniτi
INBi,
1
τ0þniτi
 
i¼1, 2, …, tm ð6Þ
Gains and Costs of Additional Follow-Up Time
At each potential decision point, the decision maker has the choice
to stop getting observations from the registry and make the deﬁnite
decision or to postpone the decision for one more year. The
expected net gains (ENGs) of continuing the registry for one more
year were found as the gains of waiting minus the costs of waiting.
Gains as Expected Value of Sample Information
Gains of waiting for more evidence before making a decision were
basically calculated as the reduction in opportunity losses (which
are the health beneﬁts forgone because of the use of suboptimal
treatment) [13,14]. Making a deﬁnite reimbursement decision
means that either oxaliplatin is going to be routinely prescribed
together with 5FU/LV or capecitabine for all patients with stage III
colon cancer in The Netherlands, or it would be completely
removed from the list of reimbursed drugs. The expected value
of sample information expresses the added value of gathering
more information before taking the deﬁnite decision. The expected
value of sample information at the end of stage i was computed as
the reduction in the opportunity loss from the end point of stage i
 1 to the end point of stage i. The opportunity loss expresses the
possible losses resulting from a wrong decision. When uncertainty
in the INB distribution is low, the possibility of a wrong decision
decreases and hence the opportunity losses also decrease. The
reduction in opportunity loss could be found from changes in the
distribution of INB after each stage. The detailed formulations of
ﬁnding the opportunity losses and expected values of sample
information are given in Appendices 3 and 4 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2014.10.008.
Number of Patients Who Beneﬁt from the Decision
The number of patients in the country who can potentially
beneﬁt from a well-informed decision after each stage multiplied
by the gain per patient gives the overall gain of continuation of
Table 1 – Population parameters used in the model.
Parameter Value Reference
Proportion of oxaliplatin users 0.7 The Dutch
registry
Population of the country 16,000,000 –
Number of prevalent cases in 2006 8,300 [15]
Number of incident cases in 2006 1,900 [15]
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patients at the end of year i, is calculated as follows:
Ni¼Ni1þðk PÞðrmoxaliplatin Ni1þð1rÞ mno oxaliplatin
 Ni1Þ ð7Þ
where k is the incidence rate, P is the total population of the
country, r is the proportion of patients who are using oxaliplatin,
and m is the mortality proportion. For the application, prevalence
and incidence rates of 2006 [15] were used to estimate the total
number of patients beneﬁting from the decision at each stage (Ni)
(Table 1).
Costs of waiting
Costs of waiting include ﬁxed costs of setting up the registry,
which take place at t0, and the variable costs of observing
patients recruited over time. Therefore, at the end of the ﬁrst
stage, the total costs (tc) would be
tc1¼cfþðn1 o þ n1 cÞ  cv ð8Þ
where cf is the registry set-up cost, cv is the incremental variable
cost per patient of being on the registry per year, and n1o and n1c
are the number of registered patients for the ﬁrst year in each
group. From the second year onwards we have
tci¼ðni oþni cÞ  cv ð9Þ
Gains versus Costs: ENG
Trading off the gains against the costs, the ENG of delaying the
decision for one more year at the end of each year can be found. If
the value of ENG turned out positive, this indicates that so far
gains had been obtained from delaying the decision. If the value
appeared negative (i.e., the cumulative ENG starts to decrease),
the decision maker could stop the observation process because
further continuation of the registry only implied more costs,
unless the registry is providing gains for other purposes. Regard-
less of the latter, this would be the best time for the decision
concerning deﬁnite reimbursement because further delay would
add no value. This is a rule of thumb, based on the assumption
that the cumulative ENG shows a single peak.
Sensitivity Analysis
The parameters related to the data and the update in INB were
determined by the case study at hand, being outcomes of theTable 2 – Speciﬁcations of disease-free survival data
based on the Dutch registry.
Treatment Survival days distribution
Oxaliplatin Weibull* (1290.93)
No oxaliplatin Weibull (14,303.4)
CDF, cumulative distribution function.
* Weibull CDF (a,b) of 1eðx=aÞb as the probability of event up to
time x.registry. Hence, for the sensitivity analysis, we focused on the
parameters that were chosen by assumption. The willingness-to-
pay threshold was varied between €20,000/disease-free life-year
and €100,000/disease-free life-year.
The base-case value for the initial distribution of INB was
based on the MOSAIC trial, which is an international multicounty
study. We used a wide uninformative prior with the mean 0 to
test how the results would change without any information
available at t0. Population statistics show that incidence and
prevalence of stage III colon cancer are increasing. Hence, we also
examined the effect of using the latest available data (i.e., data in
2012) on incidence and prevalence in The Netherlands.Results
Simulating the Remainder of the Registry
The scale parameter(a) and the shape parameter (b) for the ﬁtted
Weibull distribution are presented in Table 2. Simulation of
future disease-free lifetime shows that most patients would have
had a relapse by the end of 2012. Please note that this simulation
would be superﬂuous in case of an empirical registry with
prospective decision making.
Survivals, Costs, and INBs
Table 3 presents results for the survival as well as treatment
costs at the end of each year, and the resulting INB. These ﬁgures
are based on actual empirical data until 2008, and after that they
are based on simulated data.
In the ﬁnal years, because of a longer observation period,
more disease-free days are observed and hence the mean is
larger. Obviously, that does not imply that mortality is
decreasing.
Prior Distribution of INBs
The DFS times of each arm and the incremental survival based on
the MOSAIC trial [12] are reported in Table 4. Expected additional
costs of oxaliplatin had been estimated to be €12,500 for a
planned treatment of 6 months.
Using Equation 3 and the information available at t0, the INB0
has the following distribution:
INB0Nð7500, 13702Þ ð10Þ
ENG of Additional Follow-Up Time
Monetary gains of waiting for each potential decision point are
reported in Table 5. Fixed costs of registry set-up were by
assumption €10,000 and the variable costs €200 per patient per
year. Table 5 also reports the resulting values for ENG and their
cumulative value after each year.
The gains of the registry when considering DFS and costs as
outcomes never exceeded zero. The ENG quickly converged to a
value of 77,400. This means that the registry did not resolve
uncertainties around the INB nor reduced the risk of the decision
(i.e., the opportunity losses). Such results indicate that if only DFS
and costs are considered as relevant outcomes, getting data from
the registry could better have been stopped after 1 year of
observation.
Sensitivity Analysis
Table 6 presents the results of the sensitivity analysis. Only a
willingness-to-pay value of as high as €100,000/disease-free life-
year gained implies a decision risk high enough to result in an
Table 3 – Number of patients observed per arm, means and standard errors of disease-free survival days, costs,
and INB using the data observed up to the end of each year for a willingness-to-pay value of €60,000/DFLY.
Year Number observed Mean disease-free survival days (SE) Mean costs (SE) (€) INB (SE)
Control Oxaliplatin Control Oxaliplatin Control Oxaliplatin
2006 103 260 640 (18) 590 (13) 5,800 (400) 17,900 (700) 20,580 (870)
2007 110 280 920 (29) 840 (20) 8,300 (490) 21,000 (660) 25,900 (970)
2008 110 280 1110 (43) 1020 (28) 9,800 (600) 23,000 (730) 28,010 (1200)
2009 110 280 1150 (47) 1050 (31) 10,900 (720) 24,500 (810) 30,650 (1350)
2010 110 280 1170 (49) 1050 (31) 11,100 (740) 24,600 (810) 32,200 (1380)
2011 110 280 1170(50) 1050 (31) 11,200 (750) 24,700 (810) 33,210 (1390)
2012 110 280 1170(50) 1050 (31) 11,200 (760) 24,700 (810) 33,040 (1390)
DFLY, disease-free life-year; INB, incremental net beneﬁt; SE, standard error.
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formative initial distribution for the INB with mean 0 rather than
negative also results in an optimal time of 2 years. That is, in
absence of information at the time of the conditional reimburse-
ment decision, only 2 years of data observation would sufﬁce for
making a deﬁnite decision. Results for the prevalence and
incidence rates indicate that the actual change in epidemiology
of the disease during the period 2006-2012 did not affect the
optimal time. Therefore, under the speciﬁc characteristics of this
case study (without inﬂow of new patients into the registry), a
maximum of 2 years of data observation appeared sufﬁcient for
informing a deﬁnite decision on reimbursement of oxaliplatin.Discussion
In this study, we evaluated the use of registry data to support the
access with evidence process for the reimbursement of oxalipla-
tin for stage III colon cancer treatment. We showed that for this
case if only DFS and costs are considered as relevant outcomes,
the data observation could have been stopped after 1 or at most 2
years, or even should not have started at all, at least for the
purpose of informing the reimbursement decision. Our study
reinforces that setting up and continuation of a registry requires
regular careful assessment of its results versus the expected
outcomes.
The setting of our study is similar to what has been called the
adopt and trial approach [13], in which the new medication is
adopted while more research is conducted to ﬁnd new evidence,
usually by means of a clinical trial with certain size and ﬁxed
ﬁnal time. Several studies have used the VOI analysis to ﬁnd the
optimal design of clinical trials (e.g., [13,14,16–19]), in particular
for the adopt and trial situation [13,14]. Bayesian techniques have
also been widely used in sample size determination [20–22]. In
contrast to the above methods, the present study evaluates the
optimal time to extract speciﬁc data from a given registry with aTable 4 – Speciﬁcations of estimates at the start
point of the conditional reimbursement period (t0).
Estimated input Mean  SD Reference
FL þ oxaliplatin survival days 900  270 [12]
FL survival days 870  300 [12]
Additional survival days
gained by oxaliplatin
30  390 [12]
Additional costs of oxaliplatin 12,500  720 Expert opinion
FL, ﬂuorouracil.known design. That is, rather than the sample size, or the
combination of sample size and follow-up time, the present
study focuses on the follow-up time of the registry, assuming
that the sample size follows from the given registry design.
Although it is theoretically superior to determine both sample
size and follow-up time together, in practice this is intractable for
more than two periods [16,18]. Regardless of the design of the
study, the basic idea to evaluate the data-gathering process
remains the trade-off that is to be made between the gains of
waiting for more information and the losses resulting from a
delayed decision.
Another related approach is the real options approach, which
has been applied in various applications, investment decisions
regarding imaging techniques [23], and medical decision making
in risky surgery [24]. Usually, however, an analytical solution can
be obtained only by imposing strict assumptions on the distribu-
tions of the parameters involved that will not be met in practice.
Especially interdependence of outcomes over time (as present in
the current data set) is a problem.
The method proposed in the present study takes into account
the VOI provided by additional observations as well as its costs.
In valuing the information it evaluates how this information will
enhance the decision to be taken on the basis of registry data. In
that sense it differs from the usual considerations in registry
design (e.g., data sources, patient selection, comparison groups,
and sampling strategies) [25].
Using VOI methods for evaluation of data-gathering proce-
dures during an AED process is consistent with a more general
decision-making approach to decision making concerning AED.
Chalkidou et al. [26] present a structured framework for this.
To choose the correct access strategy using evidence-based
decision making, four distinct but connected questions need to
be answered: 1) Does current evidence suggest that the innova-
tion is better than current practice? 2) Is further research worth-
while? and 3) Should a deﬁnite decision be delayed until more
information becomes available? The present article adds a fourth
and related question 4) What is the best time for reevaluation?
To address question 2, VOI analysis is helpful. This may be
either a simple expected value of perfect information to show
that further research is not worthwhile or a more elaborate
analysis, to investigate whether certain types of research are
worth their costs. Once it turns out that further research is
worthwhile, the next question must be addressed. Questions 3
and 4 are related, in the sense that if 3 implies that a deﬁnite
decision should not be delayed, this means that the best time for
reevaluation is now (that is a zero delay). However, when delay is
appropriate, the next question is by how much.
Although the original framework leaves out this fourth ques-
tion, it has been addressed by Eckerman and Willan [13] in a
setting with randomized trials being used for gathering
Table 5 – ENGs of delaying the decision after each year (numbers are rounded).
Year Expected gains Total costs ENG* Cumulative ENG
2006 0 81,800 81,800 81,800
2007 0 77,400 77,400 159,200
2008 0 77,400 77,400 236,600
2009 0 77,400 77,400 314,000
2010 0 77,400 77,400 391,400
2011 0 77,400 77,400 468,800
2012 0 77,400 77,400 546,200
ENG, expected net gain.
* Number of patients and willingness-to-pay value used for calculations are reported in Table 3.
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answer questions 3 and 4 simultaneously, assuming a registry is
going on to provide the answer to these questions.
In theory, a more comprehensive approach may be to start
with the complete disease model (usually a Markov model) used
for the initial decision at t0 (hence when addressing question 1 in
the above-mentioned framework), parameterizing all relevant
uncertainties and resulting in an estimated INB. To update the
INB in each stage/period would then involve using the registry
data available at that moment to reestimate all relevant param-
eters and redo the model calculations to ﬁnd a new INB. This may
be quite time consuming. In the present article, we simpliﬁed the
procedure by applying a simpliﬁed disease model containing only
two distributions for survival and costs to result in an approx-
imate INB. For the purpose of setting the best follow-up time,
such a simpliﬁed model focusing on the most relevant parame-
ters is handy because it allows easier reestimation. The selection
of the most relevant parameters could be informed by a sensi-
tivity analysis performed on the full disease model including a
VOI analysis. If this VOI analysis (to be conducted to answer
question 2 of the framework) indicates that other parameters
than costs and survival are more relevant for informing the
reevaluation, then a different model for calculating approximate
INBs in each stage might be needed. Whatever disease model is
applied, the general approach remains the same: repeatedly
estimate the INB and evaluate how the new data add to its
precision.
The aims that the registry is meant to support must be well
deﬁned beforehand. For example, the aim might be to gather
information on implementation issues in daily care such as
actual treatment costs or survivals. It might also be supporting
a better informed decision on effectiveness or other outcomes for
patients. Very often registries are designed to inform more than
one parameter. For instance, the real-world data studied in the
present article have been shown to be very helpful in comparingTable 6 – Sensitivity analysis.
Parameter Base-case assumption/value
Willingness to pay €60,000/DFLY
Prior distribution N(7500,13702)
Prevalence proportion 0.052% (2006)
Incidence proportion 0.012%
DFLY, disease-free life-year.guidelines to daily practice with respect to treatment choice [10].
When a registry is aiming to provide information on conditional
reimbursement decisions, the requirements of such decision
must be met (e.g., the outcome measurement and perspective).
Our model, however, focuses on one speciﬁc decision objec-
tive (INB) in this case, covering two parameters (DFS and medical
costs). The INB was considered the most relevant outcome for a
reimbursement decision and hence taken as the outcome of
interest for the issue of timing the reevaluation. Quality-
adjusted life-years gained would have been a worthwhile alter-
native health beneﬁt measure; however, too little information
was available to calculate these. Our method would not change
substantially when using quality-adjusted life-years rather than
life-days gained as an outcome. That is, the example may be
generalized to other outcomes. The method does require a net
beneﬁt to be calculated but is not speciﬁc about what outcomes
are used to calculate this net beneﬁt.
Our approach allows comparing two treatments only because
it uses INBs. For the conditional reimbursement setting, compar-
ing two treatments is quite relevant, with one of the treatments
being the new drug and the other reﬂecting the care as usual,
possibly a mixture of treatments.
Like any observational study, registry data are inevitably
biased. Although solutions for this exist, for the real-world data
used in the present study, patient heterogeneity turned out to be
too large to allow for appropriate correction of confounding in the
registry data. This resulted in problems in estimating incremen-
tal cost-effectiveness using the registry data only [27]. As a
solution, a recent study [28] has combined the registry data with
the data from the MOSAIC trial [12] and the long-term follow-up
data of the trial [29] to ﬁnd the cost-effectiveness of oxaliplatin.
Our present case study is intended to illustrate the approach and
hence we did not explicitly deal with these biases in the data and
just presented the uncorrected outcomes. In real-world applica-
tions, proper corrections should be included. Alternatively forAssumption/value in
sensitivity analysis
Optimal registry time in
sensitivity analysis (y)
€20,000/DFLY 1
€40,000/DFLY 1
€80,000/DFLY 1
€100,000/DFLY 2
N(0,100002) 2
0.065% (2012) 1
0.014% (2012) 1
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conﬁrm outcomes for the intervention arm only, rather than the
INB. That would result in net beneﬁts being updated. It should be
noted that even if the registry data can be successfully corrected
for bias, it might not yet be worthwhile to gather additional data
from it. Initiation and continuation of a registry is costly, and if
the gain in information is small for the purpose(s) that the
registry is meant to achieve, it is better to stop the registry and
avoid extra costs or not to start it at all.
The registry evaluation was modeled as a so-called wait-and-
see process. In this approach, the data gathering is stopped once
a low (negative) registry net gain value is observed. This implies
that a decision concerning registry continuation or cessation will
be taken after the registry has already started. Hence, an a priori
clear idea of the duration of the registry would not be available.
Generally, one would strive to make the deﬁnite reimbursement
decision right after the optimal length of the observation period,
that is, when the amount of information contained has been
achieved and processed. This length will change for different
drugs and conditions, and though the procedures followed would
be clear, their timing may be indeterminate. This might cause
inconvenience for the policymaker, registry researchers, and
producers applying for reimbursement. One way to avoid this
problem might be to use simulation at t0 and determine the
optimal registry length a priori. Using an entirely simulated data
set, however, would increase the uncertainty in the results. In
practice, a balance will have to be struck between well- informed
decisions (requiring a long actual follow-up time) and timely
reconsideration of the length of follow-up.
To conclude, the present article described a way to approach
registries by regular reevaluation determining the best time for a
deﬁnite decision concerning reimbursement. Its ﬁndings underline
that patient registries should not be considered a standard recipe
for all AED procedures. Rather, they require careful design and
should be used in the proper population and for the proper period,
answering the proper research question. Continuation of the
registry to support a reimbursement decision while it is generating
little gain in information can cause losses; hence, it is essential to
track its gains from the start and regularly reevaluate it.Acknowledgments
We thank Dr. Wilbert van den Hout, discussant of a previous
version of this article at LolaHESG meeting in May 2013, for his
precise review of the article and the helpful comment. The
members of the LolaHESG 2013 audience who contributed to the
discussion are also thanked for a number of helpful suggestions.
Furthermore, we thank the Dutch colorectal cancer group research-
ers who undertook the Capecitabine, Inotecan, and Oxaliplatin in
advanced colorectal cancer studies for their cooperation.
Source of ﬁnancial support: This study was supported by The
Netherlands Organization for Health Research and Development
(ZonMw), project number 152002031. The funding agreement
ensured the authors’ independence in designing the study, inter-
preting the data, and writing and publishing the report. Studies
supported by ZonMw are free to be published in scientiﬁc journals.Supplemental Materials
Supplementary material accompanying this article can be found
in the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2014.10.008 or, if a hard copy of article, at www.valueinhealth
journal.com/issues (select volume, issue, and article).R E F E R E N C E S[1] Procedure voorwaardelijk toelating geneeskundige zorg. Diemen,
Netherlands: College voor zorgverzekeringen (CVZ), 2012.
[2] Eckermann S, Karnon J, Willan AR. The value of value of information:
best informing research design and prioritization using current
methods. Pharmacoeconomics 2010;28:699–709.
[3] Grifﬁn S, Welton NJ, Claxton K. Exploring the research decision space:
the expected value of information for sequential research designs. Med
Decis Making 2010;30:155–62.
[4] Conti S, Claxton K. Dimensions of design space: a decision-theoretic
approach to optimal research design. Med Decis Making 2009;29:643–60.
[5] Dugas M, Lange M, Berdel WE, et al. Workﬂow to improve patient
recruitment for clinical trials within hospital information systems—
a case-study. Trials 2008;9:2–7.
[6] Indurkhya A, Mitra N, Schrag D. Using propensity scores to estimate the
cost-effectiveness of medical therapies. Stat Med 2006;26:1561–76.
[7] Gliklich R, DeFilippo Mack C. Clinical trials vs registries. Appl Clin Trials
2009;March:1–4.
[8] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence
and mortality patterns in Europe: estimates for 40 countries in 2012.
Eur J Cancer 2013;49:1374–403.
[9] Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and
ﬂuorouracil for adjuvant therapy of resected colon carcinoma. N Engl J
Med 1990;322:352–8.
[10] van Gils CW, Koopman M, Mol L, et al. Adjuvant chemotherapy in stage
III colon cancer: guideline implementation, patterns of use and
outcomes in daily practice in The Netherlands. Acta Oncologica
2012;51:57–64.
[11] Christensen R, Johnson W, Branscum A, et al. Bayesian Ideas and Data
Analysis: An Introduction for Scientists and Statisticians. Boca Raton,
Florida: CRC Press, 2010.
[12] André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, ﬂuorouracil, and
leucovorin as adjuvant treatment for colon cancer. N Engl J Med
2004;350:2343–51.
[13] Eckermann S, Willan AR. Expected value of information and decision
making in HTA. Health Econ 2007;16:195–209.
[14] Eckermann S, Willan AR. The option value of delay in health
technology assessment. Med Decis Making 2008;28:300–5.
[15] Dutch Cancer Registry. Available from: http://www.cijfersoverkanker.
nl/. [Accessed January 21, 2012].
[16] Chen MH, Willan AR. Determining optimal sample sizes for multistage
adaptive randomized clinical trials from an industry perspective using
value of information methods. Clin Trials 2013;10:54–62.
[17] Willan A. Optimal sample size determinations from an industry
perspective based on the expected value of information. Clin Trials
2008;5:587–94.
[18] Willan A, Kowgier M. Determining optimal sample sizes for multi-stage
randomized clinical trials using value of information methods. Clin
Trials 2008;5:289–300.
[19] Willan A, Pinto E. The expected value of information and optimal
clinical trial design. Stat Med 2006;24:1791–806.
[20] Halpern J, Brown BJ, Hornberger J. The sample size for a clinical trial:
a Bayesian-decision theoretic approach. Stat Med 2001;20:841–58.
[21] Kikuchi T, Pezeshk H, Gittins J. A Bayesian cost-beneﬁt approach to the
determination of sample size in clinical trials. Stat Med 2008;27:68–82.
[22] Pezeshk H, Gittins J. A fully Bayesian approach to calculating sample
sizes for clinical trials with binary response. Drug Inf J 2002;36:143–50.
[23] Pertile P, Torri E, Flor L, Tardivo S. The timing of adoption of positron
emission tomography: a real options approach. Health Care Manage Sci
2009;12:217–27.
[24] Palmer S, Smith PC. Incorporating option values into the economic
evaluation of health care technologies. J Health Econ 2000;19:755–66.
[25] Registry design. In: Gliklich R, Dreyer N, eds. Registries for Evaluating
Patient Outcomes: A User’s Guide. Rockville, MD: Agency for Healthcare
Research and Quality, 2010: (chap 3).
[26] Chalkidou K, Lord J, Fischer A, Littlejohns P. Evidence-based decision
making: when should we wait for more information? Health Aff
(Millwood) 2008;27:1642–53.
[27] Franken MG, van Gils CW, Gaultney JG, et al. Practical feasibility of
outcomes research in oncology: lessons learned in assessing drug use
and cost-effectiveness in The Netherlands. Eur J Cancer 2013;49:8–16.
[28] van Gils CWM, de Groot S, Redekop WK, et al. Real-world cost-
effectiveness of oxaliplatin in stage III colon cancer: a synthesis of
clinical trial and daily practice evidence. Pharmacoeconomics
2013;31:703–18.
[29] André T, Boni C, Navarro M, et al. Improved overall survival with
oxaliplatin, ﬂuorouracil, and leucovorin as adjuvant treatment in stage
II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16.
